Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Registry

Journal of Clinical Apheresis

Volumn 23, Issue 4, 2008, Pages 129-137

  George, James N ^a,b   Terrell, Deirdra R ^a,b   Swisher, Karen K ^b   Vesely, Sara K ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

ADAMTS13; Plasma exchange; Pregnancy; Quinine

Indexed keywords

ACETYLSALICYLIC ACID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLEEDING; COGNITIVE DEFECT; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HUMAN; MEDICAL ASSESSMENT; MORTALITY; PATHOGENESIS; PLASMAPHERESIS; PNEUMOTHORAX; PROTEIN DEFICIENCY; PROTEIN FUNCTION; QUALITY OF LIFE; REGISTER; RELAPSE; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES;

ADAM PROTEINS; COGNITION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; OKLAHOMA; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; QUALITY OF LIFE; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 51749099766     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20169     Document Type: Article

References (44)

1. Johnson KK, Duvall D, Smith JW, Gilcher RO, Terrell DR, Vesely SK, George JN. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: a community service. J Okla State Med Assoc 2007;100:273-278.
2. Johnson KK, Terrell DR, Vesely SK, George JN: The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: a resource for medical education. J Okla State Med Assoc 2007;100:309-314.
3. U.S. Census Bureau; Census 2000 Summary File 2; using American Fact Finder. Available at http://factfinder.census.gov (August 27, 2004). 2004. (Internet Communication)
4. Vesely SK, George JN, Lämmle B, Studt J-D, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;101:60-68.
5. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthater M, Lammle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
6. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002;100:710-713.
7. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93-100.
8. Kremer Hovinga JA, Mottini M, Lämmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF72 assay: comparison with other assay methods. J Thromb Haemost 2006;4:1146-1149.
9. Clark WF, Garg AX, Blake PG, Rock GA, Heidenhwin AP, Sackett DL. Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 2003;290:1351-1355.
10. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-397.
11. Francis KK, Kojouri K, George JN. Occult systemic carcinoma masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Commun Oncol 2005;2:339-343.
12. Terrell DR, Williams LA, Vesely SK, Lammle B, Kremer Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS13 deficiency. J Thromb Haemost 2005;3:1432-1436.
13. Rock GA, Shumak K, Kelton J, Blanchette VS, Buskard N, Nair R, Spasoff R. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992;32:710-714.
14. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF. Longterm renal prognosis of diarrhea-associated hemolytic uremic syndrome. A systematic review, meta-analysis, and meta-regression. JAMA 2003;290:1360-1370.
15. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073-1086.
16. Karpac CA, Li X, Terrell DR, et al: Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008; 141:696-707.
17. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Prac Res Clin Haematol 2001;14:437-454.
18. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome Blood 2006;108:1267-1279.
19. Laszik ZG, Silva FG. Hemolytic uremic syndrome, thrombotic thrombocytopenia purpura, and other thrombotic microangiopathies and coagulopathies. In: Jennett JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's Pathology of the Kidney. Philadelphia: Lippincott Williams & Wilkins. 2007. pp 699-762.
20. George JN. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. Bone Marrow Transplant 2008;41:917-918.
21. Moore RD. Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. Am J Hematol 1999;60:116-120.
22. Brecher ME, Hay SN, Park YA. Is it HIV TTP or HIV associated thrombotic microangiopathy. J Clin Apheresis, in press.
23. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006;107:528-534.
24. Nguyen TC, Liu A, Liu L, Ball C, Choi H, May WS, Aboulfatova K, Bergeron AL, Dong JF. Acquired ADAMTS13 deficiency in pediatric patients with severe sepsis. Haematologia 2007;92:121-124.
25. Uemura M, Fujimura. Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Morioka C, Yoshiji H, Tsujimoto T, Kurumatani N, Fukui H. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008;99:1019-1029.
26. Johnson KK, Terrell DR, Lammle B, Kremer Hovinga JA, George JN, Vesely SK. Predicting risk for relapse in patients who have recovered from thrombotic thrombocytopenic purpura. Blood 2006;108:31a.
27. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966;45:139-159.
28. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003;10:339-344.
29. McMinn JR, George JN. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apheresis 2001;16:202-209.
30. Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lämmle B, Kremer Hovinga JA, George JN. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura: report of five patients with a systematic review of the literature. Haematologica 2007;92:936-943.
31. Cserti CM, Landaw SA, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apheresis 2007;22:21-25.
32. George JN, Vesely SK, Terrell DR. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004;41:60-67.
33. Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN: Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 cases and a systematic review of the literature. Oncologist 2007;12:11-19.
34. Egan JA, Bandarenko N, Hay SN, Paradowski L, Goldberg R, Nickeleit V, Brecher ME. Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenic purpura. J Clin Apheresis 2004; 19:125-129.
35. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis 2006;21:49-56.
36. Nguyen L, Li X, Terrell DR, Vesely SK, George JN. Efficacy of twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura. Transfusion 2007;48: 349-357.
37. Swisher KK, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, George JN. Clinical outcomes in patients with ADAMTS13-deficient thrombotic thrombocytopenic purpura who received platelet transfusions. Blood 2007;110:392-392a.
38. Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JN, Gilcher RO. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2000;40:896-901.
39. McMinn JR, Thomas IA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: an additional study of 78 consecutive patients. Transfusion 2003;43:415-416.
40. Howard MA, Williams LA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. III. An additional study of 57 consecutive patients, 2002-2005. Transfusion 2006;46:154-156.
41. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1727 procedures. J Clin Apheresis 2007;22:270-276.
42. Howard MA, Duvall D, Terrell DR, Christopher A, Thomas I, Holloway N, Vesely SK, George JN. A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the six year experience of the Oklahoma TTP-HUS Study Group. J Clin Apheresis 2003; 18:16-20.
43. Lewis QF, Terrell DR, Vesely SK, George JN. Long-term abnormalities of patient-reported outcomes after recovery from thrombotic thrombocytopenic purpura (TTP) using health-related quality-of-life (QOL) measurements. Blood 2006;108:139a-140a.
44. Lewis QF, Scott JG, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, George JN. Neurocognitive impairment follow- ing recovery from ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood 2007;110:395-395a.